8 Best Gene-Editing Stocks to Buy

6. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Holders: 31 

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a clinical-stage biotechnology company focused on developing gene-editing therapies using CRISPR/Cas9 technology to treat severe genetic diseases and cancers. The company specializes in both in vivo (inside the body) and ex vivo (outside the body) therapies, with a strong emphasis on in vivo approaches.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is focused on developing gene-editing therapies for diseases with high unmet needs, such as hereditary angioedema (HAE), transthyretin amyloidosis (ATTR), and alpha-1 antitrypsin deficiency (AATD). Their lead therapies, like NTLA-2002 for HAE and NTLA-2001 for ATTR, aim to offer curative, single-dose treatments, potentially disrupting multi-billion dollar markets. The company is also exploring applications in immuno-oncology and autoimmune diseases.

In recent developments, Intellia Therapeutics, Inc. (NASDAQ:NTLA) is progressing with Phase 3 studies for HAE and ATTR, with plans to complete enrollment in the HAELO study by 2025. Positive results from its Phase 1 trial of Nex-z for ATTR show promising reductions in transthyretin protein, which could slow disease progression.

Financially, the company reported $861.7 million in cash as of December 31, 2024, and is expected to fund operations through 2027. Collaboration revenue surged to $12.9 million, signaling strong progress in its partnerships. However, the corporation continues to invest heavily in R&D, with R&D expenses rising to $116.9 million. Despite these investments, Intellia Therapeutics, Inc. (NASDAQ:NTLA) anticipates a 5% to 10% reduction in operating expenses in 2025 due to a restructuring plan.